We are committed to developing safer and more effective therapeutic products that we believe represent substantial improvements over existing therapies, and that will create significant value for our shareholders.
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes MultiStem, a nonembryonic stem cell product candidate for the treatment of multiple disease indications. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders, such as narcolepsy, excessive daytime sleepiness, and chronic fatigue associated with Parkinson?s disease; and other potential indications, such as attention deficit hyperactivity disorder and cognitive disorders, which include schizophrenia. In addition, Athersys, Inc., through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for a range of disease indications, including ischemic injury and cardiovascular disease, certain neurological diseases, autoimmune diseases, transplant support, and various orphan disease indications. The company was founded in 1995 and is based in Cleveland, Ohio.
| || |
Chairman and CEO
Executive Vice President and Chief Scientific Officer
President and Chief Operating Officer
Executive Vice President, Regenerative Medicine
Vice President of Finance
- Gil Van Bokkelen Ph.D.
Dr. Van Bokkelen has served as our Chief Executive Officer and Chairman since August 2000. Dr. Van Bokkelen co-founded Athersys in October 1995 and served as Chief Executive Officer and Director since Athersys' founding. Prior to May 2006, he also served as Athersys' President. Dr. Van Bokkelen is the current Chairman of the Alliance for Regenerative Medicine, a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine. He is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine, and serves on a number of other boards, including the Biotechnology Industry Organization's ECS board of directors (from 2001 to 2004, and from 2008 to present), the McGowan Institute for Regenerative Medicine and the Regenerative Medicine Foundation. He received his Ph.D. in Genetics from Stanford University, his B.A. in Economics from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of California at Berkeley.
- John Harrington Ph.D.
Dr. Harrington co-founded Athersys in October 1995 and has served as Athersys' Executive Vice President and Chief Scientific Officer and as a director since Athersys' founding. Dr. Harrington led the development of the RAGE technology as well as its application for gene discovery, drug discovery and commercial protein production applications. He is a listed inventor on 20 issued or pending U.S. patents, has authored 20 scientific publications, and has received numerous awards for his work, including being named one of the top international young scientists by MIT Technology Review in 2002. Dr. Harrington has overseen the therapeutic product development programs at Athersys since their inception, and during his career he has also held positions at Amgen and Scripps Clinic. He received his Ph.D. in Cancer Biology from Stanford University and his B.A. in Biochemistry and Cell Biology from the University of California at San Diego.
- William (B.J.) Lehmann J.D.
William (BJ) Lehmann, Jr., J.D. joined Athersys in September 2001 and was Athersys' Executive Vice President of Corporate Development and Finance from August 2002 until May 2006, when he became Athersys' President. From 1994 to 2001, Mr. Lehmann was with McKinsey & Company, Inc., an international management consulting firm, where he focused on company strategy and marketing issues, and worked extensively with new technology and service-based businesses in the firm's Business Building practice. Prior to joining McKinsey, he worked at Wilson, Sonsini, Goodrich & Rosati, a Silicon Valley law firm, and worked with First Chicago Corporation, a financial institution. Mr. Lehmann received his J.D. from Stanford University, his M.B.A. from the University of Chicago, and his B.A. from the University of Notre Dame.
- Robert Deans Ph.D.
Dr. Deans has led Athersys' regenerative medicine research and development activities since February 2003 and has served as Vice President of Regenerative Medicine since October 2003. He was named Executive Vice President of Regenerative Medicine in April 2011. Dr. Deans is highly regarded as an expert in stem cell therapeutics, with over fifteen years of experience in this field. From 2001 to 2003, Dr. Deans worked for early-stage biotechnology companies. Dr. Deans was formerly the Vice President of Research at Osiris Therapeutics, Inc., a biotechnology company, from 1998 to 2001 and Director of Research and Development with the Immunotherapy Division of Baxter International, Inc., a global healthcare company, from 1992 to 1998. Dr. Deans was also previously on faculty at USC Medical School in Los Angeles, between 1981 and 1998, in the departments of Microbiology and Neurology at the Norris Comprehensive Cancer Center. Dr. Deans was an undergraduate at MIT, received his Ph.D. at the University of Michigan, and did his post-doctoral work at UCLA in Los Angeles.
- Laura Campbell
Laura Campbell joined Athersys in January 1998 as Controller and has served as Vice President of Finance since May 2006. Prior to joining Athersys, she was at Ernst & Young LLP, a public accounting firm, for 11 years, in the audit practice. During her tenure with Ernst & Young LLP, Ms. Campbell specialized in entrepreneurial services and the biotechnology industry sector and participated in several initial public offerings. Ms. Campbell received her B.S., with distinction, in Business Administration from The Ohio State University.
Board of directors
(Please check the lastest 8-K where an investment firm was willing to pay $4.10 for 5M shares after paying $2.50 for the same amount one month earlier)
Events and presentations
. Video's of 2013 you should watch
Posted January 26th 2014
ARM 2013 Regenerative medicine Analyst report. Dr. Gil from Athersys Inc. is here, second row on the left. Approx. 35 min. http://www.youtube.com/watch?v=1FUmHXCNTJw
Case University Hospital "Possible Patient" in blind study. Short film. http://www.youtube.com/watch?v=bRRTRa7ZEyY
Company presentation at Regen Investors Conf. 18 min. To invest in this company you MUST watch this video. Very Informative ! http://www.youtube.com/watch?v=gdDJJMpCEyI
Last Conf. Call on Nov. 14th 2013. I believe this too is a must listen. http://ir.athersys.com/eventdetail.cfm?eventid=136416